Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Payables (2016 - 2023)

Rapid Therapeutic Science Laboratories' Payables history spans 8 years, with the latest figure at $1.6 million for Q2 2023.

  • For Q2 2023, Payables rose 14.18% year-over-year to $1.6 million; the TTM value through Jun 2023 reached $1.6 million, up 14.18%, while the annual FY2022 figure was $1.7 million, 9.4% up from the prior year.
  • Payables for Q2 2023 was $1.6 million at Rapid Therapeutic Science Laboratories, up from $1.6 million in the prior quarter.
  • Across five years, Payables topped out at $3.1 million in Q1 2022 and bottomed at $19652.0 in Q1 2019.
  • The 5-year median for Payables is $594725.5 (2020), against an average of $853718.0.
  • The largest annual shift saw Payables tumbled 97.01% in 2019 before it skyrocketed 4412.66% in 2022.
  • A 5-year view of Payables shows it stood at $117082.0 in 2019, then skyrocketed by 572.37% to $787225.0 in 2020, then skyrocketed by 98.79% to $1.6 million in 2021, then increased by 9.4% to $1.7 million in 2022, then decreased by 5.87% to $1.6 million in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Payables are $1.6 million (Q2 2023), $1.6 million (Q1 2023), and $1.7 million (Q4 2022).